Pharvaris (NASDAQ:PHVS) Sees Strong Trading Volume – What’s Next?

Pharvaris N.V. (NASDAQ:PHVS) saw strong trading volume on Thursday . 724,674 shares were traded during trading, an increase of 162% from the previous session’s volume of 276,677 shares.The stock last traded at $36.1690 and had previously closed at $35.92.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on PHVS shares. Royal Bank Of Canada lowered their price target on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a report on Monday, April 6th. Wall Street Zen raised shares of Pharvaris from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Wedbush raised their target price on Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a research note on Tuesday, April 7th. Morgan Stanley lifted their target price on Pharvaris from $41.00 to $46.00 and gave the stock an “overweight” rating in a research report on Thursday, June 25th. Finally, Wolfe Research began coverage on Pharvaris in a research note on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price target on the stock. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Pharvaris currently has an average rating of “Moderate Buy” and a consensus target price of $49.64.

Pharvaris Stock Down 0.1%

The firm has a market cap of $2.35 billion, a P/E ratio of -11.28 and a beta of -2.34. The business’s 50 day moving average is $31.45 and its 200-day moving average is $28.57.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.82) by $0.12. As a group, equities analysts predict that Pharvaris N.V. will post -3.2 earnings per share for the current year.

Insider Transactions at Pharvaris

In other Pharvaris news, insider Anne Lesage sold 27,872 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $35.48, for a total transaction of $988,898.56. Following the sale, the insider owned 58,750 shares in the company, valued at $2,084,450. This represents a 32.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Viviane Monges sold 9,667 shares of Pharvaris stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $30.29, for a total value of $292,813.43. Following the completion of the transaction, the director owned 5,500 shares of the company’s stock, valued at approximately $166,595. The trade was a 63.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 305,648 shares of company stock valued at $9,811,616 over the last 90 days. Corporate insiders own 11.84% of the company’s stock.

Institutional Trading of Pharvaris

Several institutional investors have recently added to or reduced their stakes in the business. General Atlantic L.P. boosted its position in shares of Pharvaris by 6.6% during the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after buying an additional 500,000 shares during the period. Foresite Capital Management IV LLC boosted its position in Pharvaris by 8.3% during the 3rd quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock worth $119,226,000 after acquiring an additional 368,000 shares during the period. venBio Partners LLC boosted its position in Pharvaris by 8.2% during the 3rd quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock worth $115,751,000 after acquiring an additional 350,000 shares during the period. Deerfield Management Company L.P. grew its stake in shares of Pharvaris by 21.1% in the third quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock worth $60,939,000 after purchasing an additional 425,000 shares in the last quarter. Finally, Commodore Capital LP grew its stake in shares of Pharvaris by 26.5% in the third quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock worth $60,341,000 after purchasing an additional 507,043 shares in the last quarter.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.